<p>波士顿 --（商业资讯）--PureTech Health plc（纳斯达克：PRTC，伦敦证券交易所：PRTC）（“PureTech” 或 “公司”），是一家致力于将科学变为现实并将创新转化为价值的中心辐射式生物治疗公司，今天宣布董事会已任命 Robert Lyne 为首席执行官（CEO）及董事会成员，立即生效。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251217152848/en/2674118/4/Robert_Lyne_Chief_Executive_Officer_PRIMARY.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251217152848/en/2674118/4/Robert_Lyne_Chief_Executive_Officer_PRIMARY.jpg"/></p>
<p>PureTech 首席执行官 Robert Lyne</p>
<p>Robert Lyne 评论道：“在 PureTech 如此重要的时刻担任首席执行官，我感到非常荣幸。在过去两年中，我亲眼见证了我们项目的实力、团队的才华以及我们差异化模式的力量。我渴望在这个基础上继续努力，与董事会紧密合作，推动执行的下一个阶段，为患者推进变革性疗法，并为我们的股东创造长期价值。</p>
<p>“我们当前的重点是确保获得资金，以推进我们最新的成立实体 Celea Therapeutics，此前我们与美国食品药品监督管理局成功召开了第二阶段结束会议。该过程正在推进，我们预计将在 2026 年上半年完成，此后 PureTech 的运营支出将显著减少。同时，我们也在积极寻求 2026 年为 Gallop Oncology 融资，因为强劲的初步顶线数据持续成熟，该项目将进入下一个发展阶段。</p>
<p>“展望未来，我们打算以精简的结构和显著降低的开支进行运营。这将与严格的投资姿态相结合，追求可以在相对适度支出下推进到关键转折点的创新举措，以改善我们的资本回报。一旦 Celea 获得全面融资，我们预计将评估向股东传递价值的最有效方式，包括潜在的资本回报，作为继续针对性和有影响力的创新的综合战略的一部分。与此同时，我们的优先事项是保护资本、保持灵活性，并为 PureTech 创造价值做好准备。”</p>
<p>PureTech 董事会临时主席 Sharon Barber-Lui 表示：“我们很高兴任命 Rob 为 PureTech 的首席执行官。作为临时首席执行官，Rob 展现了强大的领导力、战略清晰度以及对业务和关键利益相关者的深刻理解。Rob 的任命使公司能够执行明确的计划，以增强战略和运营重点，并优化股东回报。董事会支持 Rob 保持精简运营模式的严格方法，同时专注于资本高效的创新，以最大化股东价值。董事会相信 Rob 是引领 PureTech 前进的合适人选。”</p>
<p>Lyne 先生自 2025 年 7 月以来担任临时首席执行官，并于 2024 年 1 月加入 PureTech 担任首席投资组合官。在担任临时首席执行官期间，Lyne 先生为业务提供了强有力的领导，监督 PureTech 各项目的进展，并推动战略和运营优先事项。他是英国上市生命科学创新和风险投资公司的经验丰富的领导者，曾担任 Arix Bioscience plc 的首席执行官。Lyne 先生在伦敦上市的生命科学公司担任高级领导职务已有十多年，拥有良好的治理和执行团队领导记录。他参与了欧洲和北美超过 80 项风险投资融资，以及多个投资组合退出和首次公开募股。</p>
<p>Lyne 先生在过去五年内曾担任 Arix Bioscience plc 的董事。根据 LR 9.6.13R，关于 Lyne 先生任命的其他细节不予披露。</p>
<p><strong>关于 PureTech Health</strong></p>
<p>PureTech Health 是一家致力于将科学变为现实并将创新转化为价值的中心辐射式生物治疗公司。我们通过一种经过验证的、资本高效的研发模型来实现这一目标，专注于具有验证药理学和未开发潜力的机会，以满足重要的患者需求。这一战略已经产生了数十个治疗候选药物，其中三个已获得美国 FDA 批准。通过识别、塑造和降低这些高信念资产的风险，并通过外部资本支持的专门结构进行规模化，我们加速了它们通往患者的路径，同时为股东创造可持续价值。</p>
<p>欲了解更多信息，请访问 www.puretechhealth.com 或在 X（前身为 Twitter）上与我们联系 @puretechh。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》定义的前瞻性声明。所有不涉及历史事实的声明应视为前瞻性声明，包括但不限于与我们对治疗候选药物及应对重大疾病的预期、我们推进项目和实现里程碑的计划、我们的未来计划、前景、发展和战略相关的声明。前瞻性声明基于当前预期，并受到已知和未知的风险、不确定性及其他重要因素的影响，这些因素可能导致实际结果、表现和成就与当前预期存在重大差异，包括但不限于在我们向 SEC 提交的 2024 年 12 月 31 日结束的 20-F 表格年报中以及其他监管文件中描述的 “风险因素”。这些前瞻性声明基于对公司当前和未来商业战略及其未来运营环境的假设。每项前瞻性声明仅在本新闻稿发布之日有效。除法律和监管要求外，我们不承担更新或修订这些前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>本公告包含根据英国市场滥用法规（EU 596/2014）第 7 条的目的而产生的内部信息，该法规因 2018 年《欧洲联盟（撤回）法案》而成为英国法律的一部分，并已修订</strong></p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTcxNTI4NDhyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTcxNTI4NDhyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251217152848/en/</p>
<p><strong>PureTech</strong></p>
<p><strong>投资者关系</strong></p>
<p>IR@puretechhealth.com</p>
<p>来源：PureTech Health plc</p>

PRTC

<p>PureTech Health plc 已任命 Robert Lyne 为首席执行官及董事会成员，立即生效。Lyne 自 2025 年 7 月以来一直担任临时首席执行官，旨在为 Celea Therapeutics 和 Gallop Oncology 确保资金，简化运营，并专注于资本高效的创新。董事会支持 Lyne 的战略方法，以最大化股东价值。Lyne 在生命科学创新和风险投资方面拥有丰富的经验</p>

<p>BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (&#34;PureTech&#34; or the &#34;Company&#34;), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately.</p>
<div class="lb-trans"><p>波士顿 --（商业资讯）--PureTech Health plc（纳斯达克：PRTC，伦敦证券交易所：PRTC）（“PureTech” 或 “公司”），是一家致力于将科学变为现实并将创新转化为价值的中心辐射式生物治疗公司，今天宣布董事会已任命 Robert Lyne 为首席执行官（CEO）及董事会成员，立即生效。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20251217152848/en/2674118/4/Robert_Lyne_Chief_Executive_Officer_PRIMARY.jpg" alt="" original-src="https://mms.businesswire.com/media/20251217152848/en/2674118/4/Robert_Lyne_Chief_Executive_Officer_PRIMARY.jpg"/></p>
<p>Robert Lyne, Chief Executive Officer of PureTech</p>
<div class="lb-trans"><p>PureTech 首席执行官 Robert Lyne</p>
</div><p>Robert Lyne commented: “I’m honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I’ve seen first-hand the strength of our programs, the talent of our team, and the power of our differentiated model. I’m keen to build on this foundation, working closely with the Board to drive the next phase of execution as we advance transformative therapies for patients and deliver long-term value for our shareholders.</p>
<div class="lb-trans"><p>Robert Lyne 评论道：“在 PureTech 如此重要的时刻担任首席执行官，我感到非常荣幸。在过去两年中，我亲眼见证了我们项目的实力、团队的才华以及我们差异化模式的力量。我渴望在这个基础上继续努力，与董事会紧密合作，推动执行的下一个阶段，为患者推进变革性疗法，并为我们的股东创造长期价值。</p>
</div><p>“Our immediate focus is on securing the funding needed to advance our newest Founded Entity, Celea Therapeutics, following the successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration. This process is progressing, and we expect to close within the first half of 2026, after which PureTech’s operational run rate will reduce significantly. In parallel, we are also actively pursuing financing in 2026 for Gallop Oncology, as the strong initial topline data continue to mature, and the program advances to the next stage of development.</p>
<div class="lb-trans"><p>“我们当前的重点是确保获得资金，以推进我们最新的成立实体 Celea Therapeutics，此前我们与美国食品药品监督管理局成功召开了第二阶段结束会议。该过程正在推进，我们预计将在 2026 年上半年完成，此后 PureTech 的运营支出将显著减少。同时，我们也在积极寻求 2026 年为 Gallop Oncology 融资，因为强劲的初步顶线数据持续成熟，该项目将进入下一个发展阶段。</p>
</div><p>“Going forward, we intend to operate with a streamlined structure and significantly reduced overhead. This will be combined with a disciplined investment posture, pursuing focused innovation initiatives that can be advanced to key inflection points with relatively modest spend to improve our return on capital. Once Celea is fully financed, we expect to evaluate the most effective means of delivering value to shareholders, including potential capital returns, as part of an integrated strategy that continues targeted and impactful innovation. In the meantime, our priority is preserving capital, maintaining flexibility, and positioning PureTech for value creation.”</p>
<div class="lb-trans"><p>“展望未来，我们打算以精简的结构和显著降低的开支进行运营。这将与严格的投资姿态相结合，追求可以在相对适度支出下推进到关键转折点的创新举措，以改善我们的资本回报。一旦 Celea 获得全面融资，我们预计将评估向股东传递价值的最有效方式，包括潜在的资本回报，作为继续针对性和有影响力的创新的综合战略的一部分。与此同时，我们的优先事项是保护资本、保持灵活性，并为 PureTech 创造价值做好准备。”</p>
</div><p>Sharon Barber-Lui, Interim Chair of PureTech’s Board of Directors, said: “We are pleased to appoint Rob as PureTech’s CEO. As Interim CEO, Rob has demonstrated strong leadership, strategic clarity, and a deep understanding of the business and key stakeholders. Rob’s appointment positions the Company to execute against a clear plan to sharpen strategic and operational focus and optimize shareholder returns. The Board supports Rob’s disciplined approach to maintaining a lean operating model whilst concentrating on capital-efficient innovation to maximize shareholder value. The Board is confident that Rob is the right person to lead PureTech forward.”</p>
<div class="lb-trans"><p>PureTech 董事会临时主席 Sharon Barber-Lui 表示：“我们很高兴任命 Rob 为 PureTech 的首席执行官。作为临时首席执行官，Rob 展现了强大的领导力、战略清晰度以及对业务和关键利益相关者的深刻理解。Rob 的任命使公司能够执行明确的计划，以增强战略和运营重点，并优化股东回报。董事会支持 Rob 保持精简运营模式的严格方法，同时专注于资本高效的创新，以最大化股东价值。董事会相信 Rob 是引领 PureTech 前进的合适人选。”</p>
</div><p>Mr. Lyne has served as Interim CEO since July 2025 and joined PureTech in January 2024 as Chief Portfolio Officer. During his time as Interim CEO, Mr. Lyne has provided strong leadership for the business, overseeing progress across PureTech’s programs and advancing strategic and operational priorities. He is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. Mr. Lyne brings more than a decade of experience in senior leadership roles at London-listed life science companies, with a strong track record in governance and executive team leadership. He has been involved in over 80 venture capital financings across Europe and North America as well as multiple portfolio exits and initial public offerings.</p>
<div class="lb-trans"><p>Lyne 先生自 2025 年 7 月以来担任临时首席执行官，并于 2024 年 1 月加入 PureTech 担任首席投资组合官。在担任临时首席执行官期间，Lyne 先生为业务提供了强有力的领导，监督 PureTech 各项目的进展，并推动战略和运营优先事项。他是英国上市生命科学创新和风险投资公司的经验丰富的领导者，曾担任 Arix Bioscience plc 的首席执行官。Lyne 先生在伦敦上市的生命科学公司担任高级领导职务已有十多年，拥有良好的治理和执行团队领导记录。他参与了欧洲和北美超过 80 项风险投资融资，以及多个投资组合退出和首次公开募股。</p>
</div><p>Mr. Lyne was previously a director of Arix Bioscience plc within the past five years. There are no other details to be disclosed in respect of Mr. Lyne’s appointment pursuant to LR 9.6.13R.</p>
<div class="lb-trans"><p>Lyne 先生在过去五年内曾担任 Arix Bioscience plc 的董事。根据 LR 9.6.13R，关于 Lyne 先生任命的其他细节不予披露。</p>
</div><p><strong>About PureTech Health</strong></p>
<div class="lb-trans"><p><strong>关于 PureTech Health</strong></p>
</div><p>PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&amp;D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders.</p>
<div class="lb-trans"><p>PureTech Health 是一家致力于将科学变为现实并将创新转化为价值的中心辐射式生物治疗公司。我们通过一种经过验证的、资本高效的研发模型来实现这一目标，专注于具有验证药理学和未开发潜力的机会，以满足重要的患者需求。这一战略已经产生了数十个治疗候选药物，其中三个已获得美国 FDA 批准。通过识别、塑造和降低这些高信念资产的风险，并通过外部资本支持的专门结构进行规模化，我们加速了它们通往患者的路径，同时为股东创造可持续价值。</p>
</div><p>For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.puretechhealth.com 或在 X（前身为 Twitter）上与我们联系 @puretechh。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption &#34;Risk Factors&#34; in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年《私人证券诉讼改革法案》定义的前瞻性声明。所有不涉及历史事实的声明应视为前瞻性声明，包括但不限于与我们对治疗候选药物及应对重大疾病的预期、我们推进项目和实现里程碑的计划、我们的未来计划、前景、发展和战略相关的声明。前瞻性声明基于当前预期，并受到已知和未知的风险、不确定性及其他重要因素的影响，这些因素可能导致实际结果、表现和成就与当前预期存在重大差异，包括但不限于在我们向 SEC 提交的 2024 年 12 月 31 日结束的 20-F 表格年报中以及其他监管文件中描述的 “风险因素”。这些前瞻性声明基于对公司当前和未来商业战略及其未来运营环境的假设。每项前瞻性声明仅在本新闻稿发布之日有效。除法律和监管要求外，我们不承担更新或修订这些前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU 596/2014) AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED</strong></p>
<div class="lb-trans"><p><strong>本公告包含根据英国市场滥用法规（EU 596/2014）第 7 条的目的而产生的内部信息，该法规因 2018 年《欧洲联盟（撤回）法案》而成为英国法律的一部分，并已修订</strong></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTcxNTI4NDhyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251217152848r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251217152848/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251217152848/en/</p>
</div><p><strong>PureTech</strong></p>
<div class="lb-trans"><p><strong>PureTech</strong></p>
</div><p><strong>Investor Relations</strong></p>
<div class="lb-trans"><p><strong>投资者关系</strong></p>
</div><p>IR@puretechhealth.com</p>
<div class="lb-trans"><p>IR@puretechhealth.com</p>
</div><p>Source: PureTech Health plc</p>
<div class="lb-trans"><p>来源：PureTech Health plc</p>
</div>

PureTech 任命 Robert Lyne 为首席执行官 | PRTC 股票新闻